<DOC>
	<DOCNO>NCT00588666</DOCNO>
	<brief_summary>Gemcitabine carboplatin two standard chemotherapy drug use treat tumor urothelial tract . These drug shrink tumor patient , generally limited amount time . This led scientist look different way treat cancer . New drug develop treat cancer work differently standard chemotherapy drug . One new class drug call 'angiogenesis-inhibitors ' . These drug attempt decrease blood supply tumor . By , may limit tumor 's source oxygen nutrient prevent tumor grow . Bevacizumab anti-angiogenic drug . In cancer colon cancer lung cancer , combine bevacizumab standard chemotherapy shrink tumor great proportion patient make patient live long use standard chemotherapy alone . This never test urothelial cancer know bevacizumab effect disease . The purpose study find effect , good and/or bad , combination gemcitabine , carboplatin , bevacizumab cancer .</brief_summary>
	<brief_title>Phase II Trial Gemcitabine , Carboplatin , Bevacizumab Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description>This phase II trial gemcitabine , carboplatin , bevacizumab chemotherapy naïve patient advanced/metastatic transitional cell carcinoma ( TCC ) urothelial tract .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologic documentation : diagnosis transitional cell carcinoma bladder , urethra , ureter , renal pelvis . Unresectable metastatic disease Ineligible cisplatin ( incurable cisplatin ) ≥ 4 week since prior RT Karnofsky Performance Status ≥ 60 % Age ≥ 18 year age Required Initial Laboratory Values : Absolute neutrophil count ≥ 1.2 x 109/L ; Platelets ≥ 100 x 109/L ; Bilirubin ≤ 1.5 time upper limit normal ( x ULN ) institution ; Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN ; Serum creatinine &lt; 2.0 calculate creatinine clearance ( CrCl ) ≥ 30 mL/min Prior treatment systemic chemotherapy ( prior intravesical therapy permit ) Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 Anticipation need major surgical procedure course study Minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 Pregnant ( positive pregnancy test ) lactate Albuminuria demonstrate urinary albumin great = 1.0 g/24 hr screen History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Inability comply study and/or followup procedure History persistent gross hematuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Myeloproliferative Disorder</keyword>
	<keyword>urinary bladder</keyword>
	<keyword>Cancer</keyword>
	<keyword>ureter</keyword>
	<keyword>renal pelvis</keyword>
	<keyword>chemotherapy</keyword>
</DOC>